Rankings
▼
Calendar
MLTX Q4 2023 Earnings — MoonLake Immunotherapeutics Revenue & Financial Results | Market Cap Arena
MLTX
MoonLake Immunotherapeutics
$1B
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$15M
Net Income
-$7M
EPS (Diluted)
$-0.12
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$12M
Free Cash Flow
-$13M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$527M
Total Liabilities
$13M
Stockholders' Equity
$496M
Cash & Equivalents
$451M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$15M
-$17M
+10.0%
Net Income
-$7M
-$2M
-284.3%
← FY 2023
All Quarters
Q1 2024 →